Also, the initiation of anti-tumor necrosis factor therapy (n = 16) reduced the severity of psoriasis (p < 0.001), levels of GlycA (463.7 ± 92.5 vs. 370.1 ± 78.5; p < 0.001) and vascular inflammation (1.93 ± 0.36 vs. 1.76 ± 0.19; p < 0.001). Here, TNF is linked to psoriasis.